Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
Cancer patients have an increased risk of developing blood clots in the veins compared to
non-cancer patients. Cancer patients who develop blood clots can lead to reduced life
expectancy, delayed cancer treatment, and decreased quality of life. Prevention is the most
effective way to decrease the complications associated with blood clots in the veins.
Although previous clinical trials have shown some benefit on the use of medication to
prevent blood clots in the veins in ambulatory cancer patients, these studies have been
inconclusive in demonstrating that existing blood thinners significantly reduce the rate of
blood clots in cancer patients. One possible explanation relates to the fact that these
studies have included a large proportion of cancer patients who are a low risk of developing
blood clots in the veins. We are proposing to identify cancer patients who are at a high
risk of developing blood clots by using a validated tool at the time of their cancer
diagnosis. The identified high risk cancer patients will be asked to participate in a trial
to test the safety and efficacy of a new oral medication that has been used to prevent blood
clots in patients undergoing surgery. We are enrolling 574 patients in 7 Canadian centres
(Ottawa, Halifax, Montreal, Vancouver, Sault Ste. Marie, Toronto and Hamilton). 287 patients
will receive the study drug and 287 will receive an inactive substance. Analysis will be
performed to assess the safety and the superiority of the study drug.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society